RTTNews | Aug 4, 2021 10:44AM EDT

10:44 Wednesday, August 4, 2021 (RTTNews.com) - Dr. Reddy's Laboratories Limited (RDY) said that it will sell its U.S. and Canada territory rights for ELYXYB (celecoxib oral solution) 25 mg/mL, to BioDelivery Sciences International Inc. (BDSI).

As per the terms of deal, Dr.Reddy's will receive U.S.$6 million upfront upon closing followed by U.S.$9 million one year from closing. Further, Dr. Reddy's is eligible to receive event based, sales based milestones and quarterly earn-out payments.

ELYXYB (previously known as DFN-15) is indicated for the acute treatment of migraine with or without aura in adults.

Read the original article on RTTNews ( https://www.rttnews.com/3215892/dr-reddy-s-labs-to-sell-u-s-and-canada-territory-rights-for-elyxyb-25-mg-ml-to-biodelivery.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved